Xvivo Perfusion AB (publ)
Stock Forecast, Prediction & Price Target
Xvivo Perfusion AB (publ) Financial Estimates
Xvivo Perfusion AB (publ) Revenue Estimates
Xvivo Perfusion AB (publ) EBITDA Estimates
Xvivo Perfusion AB (publ) Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| SEK258.38M N/A | SEK415.29M 60.72% | SEK597.54M 43.88% | Avg: SEK1.08B Low: SEK1.08B High: SEK1.08B avg. 81.57% | Avg: SEK1.47B Low: SEK1.47B High: SEK1.47B avg. 36.15% | Avg: SEK2.17B Low: SEK2.17B High: SEK2.17B avg. 47.50% | Avg: SEK2.48B Low: SEK2.48B High: SEK2.48B avg. 13.90% |
Net Income
% change YoY
| SEK8.15M N/A | SEK18.42M 126.04% | SEK91.82M 398.29% | Avg: SEK166.83M Low: SEK166.83M High: SEK166.83M avg. 81.70% | Avg: SEK268.03M Low: SEK268.03M High: SEK268.03M avg. 60.65% | Avg: SEK0 Low: SEK0 High: SEK0 avg. -100% | Avg: SEK0 Low: SEK0 High: SEK0 avg. 0% |
EBITDA
% change YoY
| SEK39.23M N/A | SEK65.34M 66.53% | SEK126.57M 93.69% | Avg: SEK101.75M Low: SEK101.75M High: SEK101.75M avg. -19.61% | Avg: SEK138.53M Low: SEK138.53M High: SEK138.53M avg. 36.15% | Avg: SEK204.35M Low: SEK204.35M High: SEK204.35M avg. 47.50% | Avg: SEK232.77M Low: SEK232.77M High: SEK232.77M avg. 13.90% |
EPS
% change YoY
| $0.28 N/A | $0.62 121.42% | $3.07 395.16% | Avg: $5.57 Low: $5.57 High: $5.57 avg. 81.54% | Avg: $8.95 Low: $8.95 High: $8.95 avg. 60.65% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% |
Operating Expenses
% change YoY
| SEK207.02M N/A | SEK292.50M 41.29% | SEK440.92M 50.74% | Avg: SEK528.91M Low: SEK528.91M High: SEK528.91M avg. 19.95% | Avg: SEK720.11M Low: SEK720.11M High: SEK720.11M avg. 36.15% | Avg: SEK1.06B Low: SEK1.06B High: SEK1.06B avg. 47.50% | Avg: SEK1.20B Low: SEK1.20B High: SEK1.20B avg. 13.90% |
FAQ
What is Xvivo Perfusion AB (publ) stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 35.58% in 2025-2028.
We have gathered data from N/A analysts. Their low estimate is 166.83M, average is 166.83M and high is 166.83M.
What is Xvivo Perfusion AB (publ) stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 44.78% in 2025-2028.
We have gathered data from N/A analysts. Their low revenue estimate is SEK1.08B, average is SEK1.08B and high is SEK1.08B.
What is Xvivo Perfusion AB (publ) stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 35.54% in 2025-2028.
We have gathered data from N/A analysts. Their low earnings per share estimate is $5.57, average is $5.57 and high is SEK5.57.